NO20003107D0 - FremgangsmÕte og reagenter for kvantifisering av fastfasereaksjoner ved bruk av fluor NMR - Google Patents

FremgangsmÕte og reagenter for kvantifisering av fastfasereaksjoner ved bruk av fluor NMR

Info

Publication number
NO20003107D0
NO20003107D0 NO20003107A NO20003107A NO20003107D0 NO 20003107 D0 NO20003107 D0 NO 20003107D0 NO 20003107 A NO20003107 A NO 20003107A NO 20003107 A NO20003107 A NO 20003107A NO 20003107 D0 NO20003107 D0 NO 20003107D0
Authority
NO
Norway
Prior art keywords
quantification
reagents
solid phase
phase reactions
fluorine nmr
Prior art date
Application number
NO20003107A
Other languages
English (en)
Other versions
NO20003107L (no
Inventor
Vasant K Nagulapalli
Edward Orton
John E Airey
Paul H Krolikowski
Original Assignee
Aventis Pharm Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1997/023920 external-priority patent/WO1998029376A1/en
Priority claimed from PCT/US1998/026512 external-priority patent/WO1999031491A1/en
Application filed by Aventis Pharm Prod Inc filed Critical Aventis Pharm Prod Inc
Publication of NO20003107D0 publication Critical patent/NO20003107D0/no
Publication of NO20003107L publication Critical patent/NO20003107L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20003107A 1997-10-17 2000-06-16 FremgangsmÕte og reagenter for kvantifisering av fastfasereaksjoner ved bruk av fluor NMR NO20003107L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US6231897P 1997-10-17 1997-10-17
US6590297P 1997-11-17 1997-11-17
PCT/US1997/023920 WO1998029376A1 (en) 1996-12-19 1997-12-17 Process for the solid phase synthesis of aldehydes, ketones, oximes, amines and hydroxamic acid compounds
PCT/US1998/026512 WO1999031491A1 (en) 1997-12-17 1998-12-14 Method and reagents for the quantification of solid-phase reactions using fluorine nmr

Publications (2)

Publication Number Publication Date
NO20003107D0 true NO20003107D0 (no) 2000-06-16
NO20003107L NO20003107L (no) 2000-07-26

Family

ID=26742119

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20001962A NO20001962L (no) 1997-10-17 2000-04-14 Terapeutisk anvendelse av kinolinderivater
NO20003107A NO20003107L (no) 1997-10-17 2000-06-16 FremgangsmÕte og reagenter for kvantifisering av fastfasereaksjoner ved bruk av fluor NMR

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20001962A NO20001962L (no) 1997-10-17 2000-04-14 Terapeutisk anvendelse av kinolinderivater

Country Status (17)

Country Link
US (1) US6376512B1 (no)
EP (1) EP1030665A4 (no)
JP (1) JP2001520193A (no)
KR (1) KR20010024533A (no)
CN (1) CN1302206A (no)
AP (1) AP2000001786A0 (no)
AU (1) AU9696198A (no)
BG (1) BG104432A (no)
BR (1) BR9814087A (no)
CA (1) CA2306825A1 (no)
EA (1) EA200000427A1 (no)
HU (1) HUP0101022A1 (no)
IL (1) IL135673A0 (no)
NO (2) NO20001962L (no)
OA (1) OA11371A (no)
PL (1) PL344977A1 (no)
WO (1) WO1999020275A1 (no)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK15532001A3 (sk) 1999-04-28 2002-06-04 Aventis Pharma Deutschland Gmbh Deriváty kyselín s dvoma arylovými zvyškami ako ligandy receptorov PPAR a farmaceutické kompozície, ktoré ich obsahujú
PT1177176E (pt) 1999-04-28 2006-08-31 Aventis Pharma Gmbh Derivados de acidos triarilicos como ligandos de receptores ppar.
US7041691B1 (en) * 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
DE60005973T2 (de) * 1999-08-27 2004-05-13 Eli Lilly And Co., Indianapolis Biaryl-oxa(thia)zolderivate und ihre verwendung als ppars modulatoren
US6414002B1 (en) 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
TW200528436A (en) 1999-09-22 2005-09-01 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
TWI262185B (en) * 1999-10-01 2006-09-21 Eisai Co Ltd Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
JP2001261654A (ja) * 2000-03-21 2001-09-26 Mitsui Chemicals Inc キノリン誘導体およびそれを有効成分として含有する核内レセプター作動薬
AU6118001A (en) * 2000-05-03 2001-11-12 Tularik Inc Combination therapeutic compositions and methods of use
US20030171399A1 (en) 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
WO2002053547A1 (fr) 2000-12-28 2002-07-11 Takeda Chemical Industries, Ltd. Derives d'acide alcanoique, procede de production et utilisation correspondants
EP1911462A3 (en) 2001-01-26 2011-11-30 Schering Corporation Compositions comprising a sterol absorption inhibitor
TWI311133B (en) 2001-04-20 2009-06-21 Eisai R&D Man Co Ltd Carboxylic acid derivativeand the salt thereof
EP1461323B1 (en) 2001-06-12 2013-10-09 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
US7371777B2 (en) 2001-08-17 2008-05-13 Eisai Co., Ltd. Cyclic compound and PPAR agonist
SE0201937D0 (sv) * 2002-06-20 2002-06-20 Astrazeneca Ab Therapeutic agents
WO2004000790A1 (en) 2002-06-20 2003-12-31 Astrazeneca Ab Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance
JP4579681B2 (ja) 2002-07-09 2010-11-10 ブリストル−マイヤーズ スクイブ カンパニー 抗糖尿病薬および抗肥満薬として有用な置換ヘテロシクロ誘導体および方法
WO2005026134A1 (en) 2003-09-17 2005-03-24 Novartis Ag Organic compounds
EP1745014B1 (en) 2004-05-05 2011-07-06 High Point Pharmaceuticals, LLC Novel compounds, their preparation and use
EP1745003B1 (en) 2004-05-05 2010-10-27 High Point Pharmaceuticals, LLC Novel compounds, their preparation and use
CN100418532C (zh) * 2005-06-17 2008-09-17 吕志民 治疗多种疾病的NF-κB化合物抑制剂
MX2007016374A (es) 2005-06-30 2008-03-05 Novo Nordisk As Acidos fenoxiaceticos como activadores ppar delta.
JP2009507846A (ja) * 2005-09-07 2009-02-26 プレキシコン，インコーポレーテッド Ｐｐａｒ活性化合物
CN103224477A (zh) 2005-12-22 2013-07-31 高点制药有限责任公司 作为PPAR-δ活化剂的苯氧基乙酸
EP1999098A2 (en) 2006-03-09 2008-12-10 High Point Pharmaceuticals, LLC Compounds that modulate ppar activity, their preparation and use
US9308198B2 (en) 2006-09-08 2016-04-12 Rhode Island Hospital Treatment, prevention, and reversal of alcohol-induced brain disease
US7645616B2 (en) 2006-10-20 2010-01-12 The University Of Hong Kong Use of lipocalin-2 as a diagnostic marker and therapeutic target
RU2522458C2 (ru) * 2008-04-30 2014-07-10 Веллстат Терапьютикс Корпорейшн Тетразольные соединения для снижения концентрации мочевой кислоты
WO2010144550A1 (en) 2009-06-09 2010-12-16 Abraxis Bioscience, Llc Triazine derivatives and their therapeutical applications
ES2557453T3 (es) 2009-06-09 2016-01-26 Nantbioscience, Inc. Derivados de isoquinolina, quinolina y quinazolina como inhibidores de la señalización de Hedgehog
WO2010144394A1 (en) 2009-06-09 2010-12-16 Abraxis Bioscience, Llc Benzyl substituted triazine derivatives and their therapeutical applications
JP5830534B2 (ja) 2010-07-09 2015-12-09 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 化合物
JP2013536165A (ja) 2010-07-12 2013-09-19 ファイザー・リミテッド 痛みの処置のためのｎａｖ１．７阻害薬としてのスルホンアミド誘導体
JP2013532186A (ja) 2010-07-12 2013-08-15 ファイザー・リミテッド 化合物
CA2804716A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
CA2801032A1 (en) 2010-07-12 2012-01-19 Pfizer Limited N-sulfonylbenzamide derivatives useful as voltage gated sodium channel inhibitors
US9102621B2 (en) 2010-07-12 2015-08-11 Pfizer Limited Acyl sulfonamide compounds
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
WO2015157187A1 (en) * 2014-04-06 2015-10-15 Sanford-Burnham Medical Research Institute Metabotropic glutamate receptor positive allosteric modulators (pams) and uses thereof
CN116323560A (zh) * 2020-08-04 2023-06-23 精密生物治疗有限责任公司 作为胆汁酸受体和白三烯半胱氨酰受体的选择性和/或双重调节剂的喹啉化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) * 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
US4920132A (en) * 1987-11-03 1990-04-24 Rorer Pharmaceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene D4
US4920130A (en) * 1987-11-02 1990-04-24 Rorer Pharamceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene D4
WO1995014669A1 (en) * 1993-11-29 1995-06-01 Merrell Pharmaceuticals Inc. Novel benzenesulfonylimine derivatives as inhibitors of il-1 action
ES2136782T3 (es) * 1994-10-27 1999-12-01 Asahi Glass Co Ltd Procedimiento para producir compuestos de acido quinolin-2-il-benzoico.
ES2217386T3 (es) * 1996-01-02 2004-11-01 Aventis Pharmaceuticals Inc. Compuestos de acido(aril, heteroaril, arilmetil o heteroarilmetil) hidroxamico sustituido.

Also Published As

Publication number Publication date
OA11371A (en) 2004-01-28
WO1999020275A1 (en) 1999-04-29
JP2001520193A (ja) 2001-10-30
NO20003107L (no) 2000-07-26
US6376512B1 (en) 2002-04-23
NO20001962D0 (no) 2000-04-14
CA2306825A1 (en) 1999-04-29
EP1030665A4 (en) 2002-11-27
KR20010024533A (ko) 2001-03-26
BR9814087A (pt) 2000-10-03
PL344977A1 (en) 2001-11-19
EA200000427A1 (ru) 2001-02-26
EP1030665A1 (en) 2000-08-30
IL135673A0 (en) 2001-05-20
AP2000001786A0 (en) 2000-04-16
BG104432A (bg) 2000-12-29
AU9696198A (en) 1999-05-10
HUP0101022A1 (hu) 2001-10-28
NO20001962L (no) 2000-06-16
CN1302206A (zh) 2001-07-04

Similar Documents

Publication Publication Date Title
NO20003107D0 (no) FremgangsmÕte og reagenter for kvantifisering av fastfasereaksjoner ved bruk av fluor NMR
NO981360D0 (no) Fremgangsmåte til sammenföyning av metalliske sammenföyningselementer ved hjelp av friksjonsagitasjon
NO955113D0 (no) Anordning og fremgangsmåte ved endostern reaksjon
DK0811128T3 (da) Fremgangsmåde til at forbinde forede røremner og røremner forbundet ved denne fremgangsmåde
EP0914349A4 (en) SYNTHESIZER WITH MULTIPLE REACTORS AND METHOD OF COMBINATORY CHEMISTRY
EP0864090A4 (en) METHOD AND APPARATUS FOR QUANTITATIVE AND SEMI-QUANTITATIVE EVALUATION OF A SUBSTANCE TO BE ANALYZED
AU1400099A (en) High-throughput method and apparatus for identifying, quantitating and determining the purity of chemical compounds in mixtures
EP0709769A3 (en) Apparatus and method for analysis and resolution of operand dependencies
EP1051583A4 (en) METHOD AND DEVICE FOR OPTICAL IMPROVEMENT OF CHEMICAL REACTIONS
DK0892035T3 (da) Flerfaseemulsion og fremgangsmåde til fremstilling heraf
BR9708036A (pt) Processo para a análise de um analito e e aparelho analitico
AU6215800A (en) Method and apparatus for rapid screening of multiphase reactions
TR199800669A3 (tr) Akrilonitrilin polimerizasyonu için islem
NO983957D0 (no) Fremgangsmåte ved sammenföyning av tofase rustfritt stål
NO20002075L (no) FremgangsmÕte ved aminering
DK1034396T3 (da) Fremgangsmåde og apparat til afskibning af superfrosne materialer
AU2001265351A1 (en) Method and analytical system for rapid screening of combinatorial libraries
NO962186D0 (no) Fremgangsmåte for fremstilling av kombinatoriske forbindelsesbiblioteker
FR2805044B1 (fr) Procede et dispositif de determination de l'evolution d'une reaction chimique dans un four et de reglage de la reaction
NO960401L (no) Fremgangsmåte ved fristempelinnretninger og anordning til utförelse av fremgangsmåten
HUP0200726A2 (en) Method and reagents for the quantification of solid-phase reactions using fluorine nmr
HK1033357A1 (en) Method for the quantification of solid-phase reactions using fluorine nmr
ID24281A (id) Metoda pembakaran suatu reaksi kimia secara induksi
NO20000182D0 (no) Fremgangsmåte for fremstilling av alkoksyfuranonaminderivater, forbindelser frembragt ved fremgangsmåten og anvendelse av disse forbindelser
AU6331298A (en) Analytical gas instrument recycle system and method

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application